The investigational once-weekly dual GLP-1/GIP receptor agonist, engineered with signaling bias at both receptors, met both primary end points at 48 weeks.
Press Release|Articles|February 29, 2024
Camber Pharmaceuticals Launches Generic Trileptal®
Oxcarbazepine Oral Suspension, USP 300 mg/5 mL is available in 250 mL bottles.
Advertisement
Camber Pharmaceuticals is pleased to announce the addition of Oxcarbazepine Oral Suspension, USP to its current portfolio.
Oxcarbazepine Oral Suspension, USP is indicated for:
- Adults as monotherapy or adjunctive therapy in the treatment of partial-onset seizures.
- Pediatrics as monotherapy in the treatment of partial-onset seizures in children 4 to 16 years of age, and as adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years of age.
Oxcarbazepine Oral Suspension, USP 300 mg/5 mL is available in 250 mL bottles.
To find out more about Oxcarbazepine Oral Suspension, USP, please visit
Advertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
2
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
5